Our CD16A/GPC3 BsAb platform addresses two unmet needs in HCC immunotherapy: (1) the lack of clinically advanced NK cell-engaging BsAbs and (2) the suboptimal synergy between existing BsAbs and TKIs. The gene discussed is GPC3; the disease is hepatocellular carcinoma.